Accessibility Menu
GlobeStar Therapeutics logo

GlobeStar Therapeutics(OTC) GSTC

Market Cap$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2016)-100%
5 Year-100%
1 Year+0%
1 Month-99%
$0.00
+0.00%
+0.00Today
GlobeStar Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-11
GlobeStar Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-07-22
1 month-99%USD 0.002026-07-09
3 month+0%USD 0.002026-05-07
Year to date+0%USD 0.002025-12-31
1 year+0%USD 0.002025-08-06
3 year-99.97%USD 0.002023-08-11
5 year-100%USD 0.042021-08-12
Since inception-100%USD 0.112016-06-23

GlobeStar Therapeutics Financials at a Glance

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$888.00K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-28.11 (Low)

Price

$0.00

Volume

565

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Oct 11, 2024

GSTC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GlobeStar Therapeutics

GlobeStar Therapeutics Corporation is a clinical-stage biopharmaceutical firm focused on developing proprietary drug formulations for multiple sclerosis and other neurodegenerative disorders. Established in 2016 and rebranded in 2021, the company operates from Richland, Washington.

Products and Services
  • Innovative drug formulations targeting multiple sclerosis
  • Research and development in neurodegenerative disorder treatments
  • Clinical trials to validate therapeutic efficacy
Growth Outlook
  • Potential market expansion in neurodegenerative therapies
  • Increased focus on clinical trials to drive product development
  • Strategic partnerships may enhance research capabilities
Financial Highlights
  • Recent quarterly net income of -198,000, reflecting ongoing investment in R&D
  • Trailing twelve months (TTM) revenue remains at zero, indicating early-stage development
  • Operating expenses totaled 193,357 in the latest quarter, primarily for administrative costs
GlobeStar Therapeutics Corporation is positioned in a niche market with significant growth potential. The focus on innovative treatments for multiple sclerosis and other neurodegenerative disorders aligns with increasing healthcare demands. Despite current financial challenges, the company's commitment to research and development may pave the way for future advancements and market opportunities. Investors may find interest in the company's strategic direction and potential for long-term growth in the biopharmaceutical sector.
AI Generated • Aug 1, 2026

Industry

Biotechnology

Sector

Health Care

CEO

James C. Katzaroff

Website

globestarthera.com

Headquarters

Richland, WA 99352, US

GSTC Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

148.30%

Return on Capital

N/A

Return on Assets

0.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.24B

Volume

565

Avg. Volume

2.59K

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$805.00K

EBITDA

-$587.60K

Operating Cash Flow

-$148.28K

Capital Expenditure

$4.00

Free Cash Flow

-$148.28K

Cash & ST Invst.

$41.00

Total Debt

$329.05K

GlobeStar Therapeutics Performance Analysis

GlobeStar Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-09-30USD 0N/A
20222022-09-30USD 0N/A
20232023-09-30USD 0N/A
GlobeStar Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-09-30N/A
Q12023-12-31N/A
Q22024-03-31N/A
Q32024-06-30N/A
GlobeStar Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-09-30USD -0.02N/A
20222022-09-30USD -0.00-88.2%
20232023-09-30USD -0.000.0%
GlobeStar Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42023-09-3073.3%
Q12023-12-3150.0%
Q22024-03-31N/A
Q32024-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2024YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$1.20KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

0

N/A

Net Income

-$198.00K

+84.6%

EBITDA

$357.00

-94.7%

Quarterly Fundamentals

Name
Q3 2024YOY CHG

Total Cash

$41.00

N/A

Total Debt

$329.05K

+1972.3%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$329.05K

+1972.3%

Return on Assets

0.00%

N/A

Return on Invested Capital

1.30%

N/A

Free Cash Flow

-$20.40K

+49.2%

Operating Cash Flow

-$20.40K

+49.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PBLAPanbela Therapeutics, Inc.
$0.00+0.00%
RGMPRegnum Corp.
$0.00+0.00%
ACUSAcusphere, Inc.
$0.00+0.00%
BIOAFBioasis Technologies Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$144.95-0.00%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$40.28+0.00%
SPCXSpace Exploration Technologies
$140.00-0.01%
NOKNokia
$10.76+0.02%

Questions About GSTC

What is the current price of GlobeStar Therapeutics?

GlobeStar Therapeutics is trading at $0.00 per share.

What is the 52-week range for GlobeStar Therapeutics?

Over the past 52 weeks, GlobeStar Therapeutics has traded between $0.00 and $0.00.

How much debt does GlobeStar Therapeutics have?

As of the most recent reporting period, GlobeStar Therapeutics reported total debt of $359.71K.

How much cash does GlobeStar Therapeutics have on hand?

GlobeStar Therapeutics reported $0.00 in cash and cash equivalents in its most recent financial results.

What is GlobeStar Therapeutics’s dividend yield?

GlobeStar Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services